Literature DB >> 15495177

Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.

Vincent L Freeman1, Mohsen Meydani, Kwan Hur, Robert C Flanigan.   

Abstract

BACKGROUND: An effect of fatty acids has been implicated in men with advanced-stage prostate carcinoma and in men who have died of the disease. To evaluate the influence of fatty acids in men with prostate carcinoma at earlier stages, the authors examined the relation between prostatic concentrations of fatty acids and locally advanced prostate carcinoma in men with clinically organ-confined disease.
METHODS: Fatty acids were measured by capillary gas chromatography in fresh, nonmalignant prostate tissue specimens collected during surgery from 196 men undergoing radical prostatectomy for localized prostate carcinoma. Two-sided, two-sample Student t tests compared mean concentrations in men with extraprostatic disease (pT3-4N0-1M0) with control men with organ-confined disease. Logistic regression accounted for clinical stage, prostate-specific antigen level, Gleason sum, and other factors.
RESULTS: Percent total prostatic polyunsaturated fatty acid (PUFA) was found to be inversely associated with risk of locally advanced prostate carcinoma (n=52) (odds ratio [OR]=0.93, 95% confidence interval [95% CI], 0.87-0.99; P=0.035). Risk of seminal vesicle involvement accounted for this association (OR=0.86, 95% CI, 0.78-0.95; P=0.003). Percent omega-3 fatty acid (eicosapentanoic + docosahexanoic acids) and percent arachidonic acid also were found to be inversely related to the risk of seminal vesicle involvement (OR=0.52, 95% CI, 0.30-0.90; P=0.02; and OR=0.84, 95% CI,; 0.75-0.95; P=0.005, respectively).
CONCLUSIONS: Prostatic PUFA levels appear to influence the risk of locally advanced prostate carcinoma in men with clinically organ-confined disease. This association may be mediated through the immune system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15495177     DOI: 10.1002/cncr.20676

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Zhennan Gu; Jansheng Wu; Yong Q Chen; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes.

Authors:  Uddhav P Kelavkar; Justin Hutzley; Kevin McHugh; Kenneth G D Allen; Anil Parwani
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

3.  Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins.

Authors:  Felix Amissah; Shalina Taylor; Randolph Duverna; Lambert T Ayuk-Takem; Nazarius S Lamango
Journal:  Eur J Lipid Sci Technol       Date:  2011-11       Impact factor: 2.679

4.  Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy.

Authors:  Uddhav P Kelavkar; Justin Hutzley; Rajiv Dhir; Paul Kim; Kenneth G D Allen; Kevin McHugh
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

5.  In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids.

Authors:  Iris J Edwards; Haiguo Sun; Yunping Hu; Isabelle M Berquin; Joseph T O'Flaherty; J Mark Cline; Lawrence L Rudel; Yong Q Chen
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

6.  A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality.

Authors:  Jorge E Chavarro; Meir J Stampfer; Megan N Hall; Howard D Sesso; Jing Ma
Journal:  Am J Clin Nutr       Date:  2008-11       Impact factor: 7.045

7.  15-lipoxygenase metabolites of docosahexaenoic acid inhibit prostate cancer cell proliferation and survival.

Authors:  Joseph T O'Flaherty; Yungping Hu; Rhonda E Wooten; David A Horita; Michael P Samuel; Michael J Thomas; Haiguo Sun; Iris J Edwards
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

8.  Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.

Authors:  Wendy Demark-Wahnefried; Stephen L George; Boyd R Switzer; Denise C Snyder; John F Madden; Thomas J Polascik; Mack T Ruffin; Robin T Vollmer
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

9.  Omega-3 Fatty Acids and PPARgamma in Cancer.

Authors:  Iris J Edwards; Joseph T O'Flaherty
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  Racial differences in distribution of fatty acids in prostate cancer and benign prostatic tissues.

Authors:  Xinchun Zhou; Hao Mei; Joshua Agee; Timera Brown; Jinghe Mao
Journal:  Lipids Health Dis       Date:  2019-11-03       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.